Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma

Inclusion Criteria:

• Diagnosis of multiple myeloma
• Diagnosis must occur on or after the formal launch of the MRD-targeted clinicalpathway in the Exigent network
• Diagnosis must be indicated by the presence of any of the following diagnosticcodes for multiple myeloma: [C90.00]
• Diagnosis must be confirmed on human review of the medical record
• Age ≥ 18 years at qualifying diagnosis.
• Patient has continued to receive care at a QCCA/Exigent Research practice for at least 90 days after the index date. Patients in the Documentation Cohort must meet the following additional inclusion criteria.

• Evidence in the record of a threshold level of adherence to the clinical pathway, orimplied intention to adhere to the clinical pathway. In addition to the inclusion criteria for the documentation cohort, patients in thePlatform Cohort must meet the following additional inclusion criteria.

• A record of registration by the patient for participation in the All4Cure platform,including signed HIPAA release forms that allow All4Cure to access their medicalrecords.
• A record of registration by the patient's primary treating physician for participationin the All4Cure platform.

Exclusion Criteria:

• Patients with a concurrent other malignancy (except basal cell carcinoma, squamouscell carcinoma of the skin, or in situ malignancies of breast or cervix), or those whohave received treatment of another malignancy within three years prior to diagnosis ofmultiple myeloma (except for treatment of basal cell carcinoma, squamous cellcarcinoma of the skin, or in situ malignancies of breast or cervix), are excluded fromeligibility.
• Patients with multiple myeloma subtypes Immunoglobulin D (IgD) or Immunoglobulin E (IgE) are excluded due to the very low rate of these subtypes.
• Patients who transfer their care to another facility outside the QCCA/Exigent Researchnetwork within the first 90 days after NDMM diagnosis are excluded.